Report: Infraredx pursues $55M IPO

Infraredx, whose intravascular near infrared spectroscopy (NIRS) technology showed promise in a recent study, has filed for an initial public offering (IPO), according to Renaissance Capital.

Results from the ATHEROREMO-IVUS (The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis–Intravascular Ultrasound) study suggested that NIRS may help cardiologists identify at-risk patients with coronary artery disease. The technology, which received FDA clearance in 2008, can detect lipid core-containing plaques in coronary blood vessels.  

Renaissance Capital reported on its IPO news site on Dec. 22 that Burlington, Mass.-based Infraredx had filed with the Securities Exchange Commission (SEC) for a public offering to raise up to $55 million. In its SEC filing, Infraredx listed revenues of $2.7 million for 2013 and revenues of $3.7 million for the nine months ended Sept. 30, 2014.

The listing on NASDAQ will be under the symbol REDX. The SEC filing is available here.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup